Perceptive Advisors has liquidated its entire stake in Sionna Therapeutics (SION), according to a recent quarterly filing. The disclosure, which reflects holdings as of September 30, 2026, shows the sale of all 905,000 shares, with an estimated trade value of $39.81 million. This exit follows a challenging period for Sionna, a clinical-stage biopharmaceutical company focused on cystic fibrosis treatments.
Investors should note that 13F filings are delayed, and this trade occurred sometime between June 30 and September 30, 2026. During this period, Sionna announced in the summer of 2026 that its experimental drug, SION-719, failed in a Phase 2a trial. This news led to a significant drop in the company's stock price and a subsequent announcement in September of a 46% workforce reduction as the company shifts focus to other drug candidates.